Introduction
creates uncertainty and controversy about the comparative eBcacy of diCerent treatments and expected outThe medical management of patients with prostate or testis cancer is based on knowledge of the biological comes for patients. Standardization of staging procedures after radical prostatectomy (RP) and clearly defining the behaviour of these malignancies, as well as factors such as the patient's age and general medical condition.
extraprostatic extension and positive surgical margins will result in significant improvements in staging. Depending on the expected prognosis, a patient may be treated with curative intent, at times enduring considerAdditional data to enhance the accuracy of staging and prediction of clinical outcome for individual patients able morbidity from the treatment. In other cases, a palliative approach, based on quality-of-life issues, may may include; systematic biopsies to predict preoperative tumour volume and a volume-based prognostic index, be the treatment of first choice. It is a challenging task to choose the optimal therapy for an individual patient linking cancer volume with extraprostatic extension, seminal vesicle invasion and lymph node metastases [5] . because of diBculties in predicting precisely the course of the malignant process in each patient. Studies on A multiple prognostic index [6] , including variables such as serum PSA, tumour volume, tumour grade, tumour tissue-related prognostic factors form an extensive part of the contemporary oncological literature. Such studies localization and DNA content, may have more predictive power than conventional staging methods alone. oCer an insight to the molecular pathogenesis of malignancies, potentially improving the power to predict the clinical course and thus assisting in clinical decisionGrade making. In this review, we discuss the clinical use of tissue-related prognostic factors in prostate and testis
The Gleason grading system is currently the most widely used system for grading prostate cancer and is a powerful cancer and assess the published literature on experimental prognostic markers. variable in the management of patients with this condition. It takes into account the histological tumour heterogeneity of prostate cancer. This feature and
Prostate cancer
tumour multifocality can result in significant sampling errors when grading is established from needle-core Prostate cancer is the commonest cancer in western men and is second only to lung cancer as a cause of biopsies [7, 8] . Furthermore, the prognostic power of grade is greatest in tumours with the lowest (2-4) or cancer death [1, 2] . As the overall lifetime probability of developing clinically evident prostate cancer is much highest (8-10) scores. However, most tumours have an intermediate score (5) (6) (7) and show strikingly heterolower than the prevalence at autopsy by the age of 80 years (16% vs 80%), most men die with rather than geneous biological aggressiveness. The Gleason score cannot discriminate the indolent from the more aggressfrom prostate cancer. However, it is clinically important to distinguish the potentially lethal from the relatively ive cancers. Also, inter-and intra-observer variability handicap the use of the Gleason score as a prognosticator indolent tumours. The use of prognostic markers may be crucial to identify the subgroup of patients with in patients with prostate cancer. aggressive prostate cancer. We will discuss both clinically applied markers and experimental markers.
PSA Since its discovery in 1971 and its purification from Stage seminal plasma and the prostate in 1979, PSA has been widely used as a tumour marker for screening, diagnosis The TNM system is the one most commonly used for clinical and pathological staging of prostate cancer [3] ;
and monitoring of prostate cancer [9] . Although the name suggests otherwise, PSA is not produced exclusit involves determining the anatomical extent of the tumour. Currently, it is associated with problems of ively by the prostate but has been detected in urine, the periurethral glands, peri-anal glands, saliva, amniotic understaging and sometimes overstaging, as shown by fluid, milk of lactating women and serum of some women be inferior to the PSA RT-PCR assay [24] but this assay requires further study. with renal cancer. PSA is not strictly organ-specific, nor is it disease-specific; elevated PSA levels can be found in a small proportion of normal men and in many men
Epithelial cadherins with BPH and prostatitis. Although PSA is not a perfect marker, many publications have confirmed the value of Epithelial cadherin (E-cadherin) is a calcium-dependent cell adhesion molecule that plays an important role in serum PSA level as a prostate cancer marker and as a surrogate endpoint for studies of locally confined prostate maintaining the epithelial phenotype. Decreased expression of E-cadherin has been detected in several cancer [10] . The role of PSA as a predictor of outcome in prostate cancer has been proposed by several investicarcinomas, and implies disordered intercellular attachment and increased risk of invasion and metastasis [25] . gators [11] . Tissue PSA has been the subject of fewer reports, although its prognostic value has been studied The role of E-cadherin in prostate cancer was reported in studies of the Dunning rat prostate cancer, in which in biopsy specimens [12] [13] [14] and TUR specimens [15] with T1b prostate cancer, indicating that PSA immuno-E-cadherin was expressed by normal rat prostate tissue and noninvasive tumours but was undetectable in invashistochemistry could predict clinical outcome. Most studies have reported that tissue and serum PSA levels are ive rat prostate cancer sub-lines [26] . In human prostate cancer an inverse correlation between E-cadherin correlated. As serum PSA is considerably easier to obtain, its value as a prognostic marker is greater than tissue expression and grade, stage and overall survival has been reported, suggesting a role for E-cadherin as a PSA. However, undiCerentiated androgen-unresponsive prostate cancer cells are unable to produce PSA, possibly prognosticator in prostate cancer [25] . More studies are needed to confirm these findings and to determine the explaining the lack of PSA increase in a proportion of patients with hormone-refractory disease. Novel appliprecise clinical importance of E-cadherin. cations of PSA, such as PSA density, PSA slope, PSA doubling time and free PSA have been derived and DNA content (ploidy) have, to a certain extent, improved the sensitivity and specificity of PSA testing [16] .
Tumour DNA content has been the subject of numerous studies of prostate cancer (reviewed by Adolfsson [27] ). Recently, research has focused on detecting circulating PSA-producing cells using RT-PCR to detect PSA-mRNA.
Many of these studies have suggested that the DNA aneuploidy of RP specimens and needle biopsies correIn one study, the presence of circulating PSA-mRNA was of independent prognostic value in predicting PSA lates with progression, metastasis and poor prognosis, although conflicting data have been presented. The progression after RP [17] . Positive results should be interpreted cautiously as the PSA gene is not uniquely clinical applicability of tumour ploidy measurements has been discussed in reports by the WHO [28] and the expressed in prostate cells and the clinical significance of single circulating tumour cells is unknown.
College of American Pathologists [29] . The former group advised the use of ploidy assessments for T2 and T3 tumours, whereas the latter group concluded that Prostate-specific membrane antigen (PSMA) DNA ploidy may be useful in patients with stage T3 or pN+ tumours who are subsequently treated with PSMA is a relatively new marker for prostate cancer [18] and is expressed by most intra-epithelial neoplasms adjuvant hormonal therapy. DNA ploidy has potential as a prognostic marker, but its clinical role remains a as well as primary and metastatic prostate cancer specimens. PSMA is also expressed at detectable levels in matter of debate. Phase-III clinical trials are needed to clarify this issue and to prove that ploidy status provides small intestine, brain and salivary gland [19] . At present, the role of PSMA as a prognostic marker for prostate information beyond stage and grade. In addition, technical issues, involving DNA determination by image cancer is inconclusive. The expression of PSMA was high in poorly diCerentiated and metastatic cancer specianalysis, need to be resolved to allow such studies to proceed. mens, but did not correlate with nodal status, seminal vesicle invasion or extraprostatic extension. The ratio of PSMA and PSMA∞, an alternatively spliced variant of Nuclear morphometry PSMA mRNA, may be a useful index for assessing prostate cancer progression [20] . Studies of serum PSMA Measurement of nuclear roundness, size, form and texture of nuclei may have prognostic value in patients reported that serum PSMA levels may serve as a prognostic marker for prostate cancer [21] [22] [23] . PSMA RT-PCR with prostate cancer [30] . However, diBculties with image analysis techniques, tissue handling and reproducassays have been developed to detect circulating PSMAproducing cells in the blood; the sensitivity appears to ibility of results remain a major concern and have prevented further evaluation of nuclear morphometry as Apoptosis a prognosticator in prostate cancer patients.
Apoptosis, or programmed cell death, may be an important factor in the response to therapy of prostate cancer 12-lipoxygenase and for prognosis. The bcl-2 protein is able to block the apoptotic pathway [39] . In normal prostate tissue bcl-2 12-lipoxygenase (12-LOX) is responsible for the production of 12(S)-hydroxy-eicosatetraenoic acid [12(S)-is expressed in the basal cell layer of glands, but not in the secretory cells. In hormone-refractory prostate cancer HETE] which plays a role in invasion and metastasis of cancer [31] . 12-LOX may serve as a correlative marker the expression of bcl-2 is markedly increased [40] suggesting that elevated levels of this protein may provide prostate for prostate cancer with an aggressive phenotype and poor prognosis, as shown by RT-PCR and in situ cancer cells with the ability to survive in an environment with no androgens. Transfection of bcl-2 into the horhybrid ization in a study comparing expression of 12-LOX in prostate cancer tissues of diCerent stages mone-dependent prostate cancer cell line LNCaP enabled these cells to survive in an androgen-depleted milieu [41] . [31] .
In one study, bcl-2 had prognostic value using univariate analysis when examining RP samples [42] and in a P53 tumour-suppressor gene further study was an independent prognosticator for time to PSA progression [43] . As apoptosis involves many Wild-type p53 protein is a suppressor of cell growth and transformation, causing inhibition of cell proliferation other proteins (such as p53, bax and bcl-X) and is related to proliferation, prognostic marker studies should be by G1 arrest and, under certain circumstances, apoptosis. Mutation on the p53 gene, which is located on the short conducted combining these factors. arm of chromosome 17, is the most common alteration in cancers. Loss of wild-type p53 function can lead to Neuroendocrine diCerentiation deregulation of the cell cycle and DNA replication, defective DNA repair, and selective growth advantage, Neuroendocrine cells are components of prostatic ducts and acini, as well as prostate cancer with neuroendocrine resulting in tumour formation and progression [32] . The role of p53 and its prognostic value in human prostate diCerentiation, which may show resistance to hormonal therapy [44] . However, most studies report no significant cancer remains unclear. A correlation between mutation of the p53 gene and tumour progression has been prognostic relevance [45] . reported in several studies, with mutations occurring as a late event in the development of prostate cancer
Other prognostic markers [33, 34] . However, other studies did not confirm this correlation [35] and suggested that p53 abnormalities
The number of studies published on prognostic markers for prostate cancer is rapidly increasing. Many new may be an early event in prostate cancer progression [36] . Larger well-defined groups of patients must be experimental markers have been described, and their clinical importance and applicability as prognosticators studied to assess definitively the prognostic value of p53 in prostate cancer. Standardization of a method of remain to be determined. These markers include microvessel density (angioneogenesis) [46] , TGFb1 [47] Another marker, hCG, is normally produced by syncytiotrophoblasts of the placenta. Normal males have ments in staging methods, surgical techniques and radiotherapy have also contributed to this favourable serum levels of the beta subunit (b-hCG) of <5 mIU/mL, but b-hCG levels are elevated in 40-60% of patients prognosis.
Nevertheless, the optimal management of patients with testicular cancer. b-hCG levels are high in all cases of choriocarcinoma, 80% of cases of embryonal cell with locally confined disease remains to be defined. Morbidity and toxicity from treatment regimens must be carcinoma and 10-25% of cases of pure seminoma [59] . Levels return to normal values normally about a week reduced, while maintaining high cure rates. Furthermore, it is important to identify those patients who are after radical tumour excision, depending on the peak serum concentration and the half-life of b-hCG. Elevated at risk of metastatic relapse. If the risk of metastasis could be determined using prognostic factors, an individually levels of AFP and b-hCG are not specific for testicular cancer and may occur with benign liver disease, and designed therapy could be oCered to the patient.
In patients with advanced nonseminomatous testicuwith lung, gastric, pancreatic, hepatocellular cancer (AFP) and breast, bladder, pancreatic, gastric, hepatocellar cancer complete remission rates are still low in some subgroups. Despite considerable progress since the lular and lung cancer (b-hCG) [58] . The enzyme LDH is responsible for lactic acid oxidation introduction of cisplatin-based chemotherapy,~20% of patients presenting with metastases die from their disease in muscle, liver and kidneys. The level of isoenzyme 1 is elevated in most patients with advanced testicular can- [54] . In this group, the goal of investigational trials is to improve the proportion of complete remissions while cers and particularly in those with large-volume tumours [58] . accepting concurrent toxicity. The application of prognostic factors might help to define a more individual Recently, international consensus on the stratification of patients with testicular cancer has been reached by treatment schedule for these patients, resulting in increased cure rates and diminished side-eCects of the International Germ Cell Cancer Collaborative Group (IGCCCG), based on data from multiple clinical trials therapy.
Among urological malignancies, testicular cancer in Europe, North America and Australia (reviewed by McCaCrey [54] ). This group found that pretreatment takes a special place because clinical decision-making is largely based on the application of prognostic factors. To levels of AFP, hCG and LDH, the site of the primary tumour and the presence of nonpulmonary visceral assess the risk for metastatic testicular cancer the most important prognostic features are the extent of the metastases were independent prognosticators for survival. Using this classification, patients with nonseminodisease and serum determination of tumour markers. matous germ cell tumours (NSGCTs) can be stratified into three groups based on response to chemotherapy Histological prognostic factors (Table 1) . Patients with seminoma patients could be divided in two risk groups; one with 'good risk', with no Histological prognostic factors include the percentage of embryonal carcinoma within the primary tumour [55] , evidence of nonpulmonary metastases, and an intermediate risk group with evidence of nonpulmonary metastand vascular invasion, i.e. the infiltration of testicular veins by the tumour. In a recent study by Lewis et al.
ases. This consensus has resulted in a new staging system for testis cancer, that incorporates both serum [56], the presence of embryonal carcinoma within the primary tumour, in addition to vascular invasion, markers and anatomical features, which is clinically relevant to the selection of patients for optimal treatment. appeared to be an independent prognostic factor for tumour progression, and the prognostic relevance was prospectively confirmed [57] .
Experimental prognostic factors
The prognostic value of DNA index, S-phase fraction and Serum tumour markers proliferation index in NSGCTs has been reported [60], but results are conflicting; in multivariate analysis these AFP, a foetal serum-binding protein, is normally found in minimal amounts (<100 ng/L) after the first year of factors were not superior to histological prognostic factors such as vascular invasion and the presence of life [58] . It is elevated in 50-70% of patients with testicular cancers, including yolk sac and embryonal embryonal carcinoma cells. 
